(NASDAQ: KURA) Kura Oncology's forecast annual revenue growth rate of 54.52% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.87%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.08%.
Kura Oncology's revenue in 2026 is $67,482,000.On average, 18 Wall Street analysts forecast KURA's revenue for 2026 to be $7,773,018,792, with the lowest KURA revenue forecast at $4,328,158,191, and the highest KURA revenue forecast at $10,573,072,152. On average, 17 Wall Street analysts forecast KURA's revenue for 2027 to be $15,793,360,909, with the lowest KURA revenue forecast at $5,237,071,411, and the highest KURA revenue forecast at $26,213,622,578.
In 2028, KURA is forecast to generate $21,540,978,327 in revenue, with the lowest revenue forecast at $7,851,278,958 and the highest revenue forecast at $39,494,001,844.